Caristo Diagnostics Limited

Caristo Diagnostics Limited is a UK-based company specializing in advanced cardiac imaging and analysis technologies aimed at improving heart disease diagnosis and prevention. Caristo Diagnostics Limited focuses on innovative cardiac imaging and analysis solutions. Founded in 2017 in Oxford, UK, the company has raised GBP 13. 03 mn through its Series A round in April 2023, led by Oxford Sciences Enterprises, with participation from BGF, Longwall Ventures, and others.

The team includes founders Charalambos Antoniades, Keith Channon, and Stefan Neubauer, who have contributed significantly to the company's vision and growth. Caristo Diagnostics specializes in advanced cardiac imaging and analysis technologies, notably their flagship products, CaRi-Heart® and CaRi-Plaque™. CaRi-Heart® employs innovative algorithms to detect hidden inflammation in coronary arteries, revolutionizing the approach to heart disease prevention and diagnosis. CaRi-Plaque™, which has received FDA clearance, provides detailed analysis of plaque formation in coronary arteries, offering healthcare professionals critical insights for preventive screening and disease management.

These products are primarily targeted at healthcare providers and clinicians, aiming to optimize diagnosis, treatment, and research related to cardiovascular health. Caristo's technologies are offered in various markets, including the United States and potentially expanding into regions such as Europe and Asia, where there is a growing demand for advanced cardiac care solutions. Caristo Diagnostics generates revenue through direct sales of its proprietary technology solutions, focusing on B2B transactions within the healthcare industry. Their core offerings, CaRi-Heart® and CaRi-Plaque™, are sold to hospitals, diagnostic centers, and other healthcare institutions, enhancing their cardiac care capabilities.

The transaction structure involves service agreements or partnerships, facilitating the integration of these technologies into existing practices. The company’s revenue model reflects the value provided through improved patient outcomes and operational efficiencies in cardiac care settings, supported by ongoing collaboration with clinical research and trials. In April 2023, Caristo Diagnostics Limited raised GBP 13. 03 mn in Series A funding to accelerate its growth in existing markets across the UK and EU.

The company plans to develop and launch new products to enhance its offerings in advanced cardiac imaging. Expansion into additional markets and regions, particularly in Europe and Asia, is a key focus, aligning with the increased demand for innovative cardiac care solutions.